Methylcobalamin (Methyl B12).

Methionine synthase takes the methyl group from methylfolate and passes it through cobalamin to homocysteine, so the two are obligate partners at that one step.

Folate cannot leave its methylated form without B12 accepting the methyl group, so folate turnover depends on cobalamin availability.

Methylcobalamin serves methionine synthase in the cytosol and adenosylcobalamin serves methylmalonyl-CoA mutase in mitochondria, so together they cover both cobalamin-dependent enzymes.

Betaine hands a methyl group to homocysteine through BHMT without needing cobalamin, so it runs a second route alongside the B12-dependent one.

The folate and B12 step regenerates methionine, which is what SAM-e is made from, so cobalamin sits upstream of the SAM pool.

B6 is the cofactor for cystathionine beta-synthase, the branch that removes homocysteine rather than recycling it, complementing the B12 remethylation route.

MTHFR needs FAD from riboflavin to make the methylfolate that cobalamin then uses, so low riboflavin status limits the substrate B12 depends on.

Cobalamin acts on DNA synthesis in the dividing precursor and iron on haemoglobin assembly, so the two occupy separate steps of the same normal process.

Choline is oxidised to betaine and feeds the same methyl pool that the B12 route replenishes, so the two spare each other.

High-dose ascorbate can degrade cobalamin when the two sit in the same solution, which is a reason to separate a large vitamin C dose from a B12 dose.

Methylcobalamin is the cofactor that lets methionine synthase remethylate homocysteine into methionine. Dietary methionine and the B12-dependent salvage route feed the same methionine pool, and when methionine intake is low the cobalamin route carries more of the load. This is settled pathway biochemistry rather than a tested combination.

The catalytic site of methionine synthase holds a zinc ion that binds and activates the homocysteine sulfur so the methyl group can be handed over from methylcobalamin. Zinc and cobalamin therefore act on the same single reaction from different sides. No combination trial is needed to describe the cofactor relationship, and none is cited here.

Serine gives up a carbon to tetrahydrofolate, which is reduced to 5-methyltetrahydrofolate, the methyl donor methylcobalamin accepts. Without one-carbon input from serine the methyl-B12 cycle has nothing to move. The link is pathway architecture, not a measured outcome.

Glycine sits on both sides of the methyl economy that methylcobalamin serves, contributing one-carbon units through the cleavage system and consuming excess S-adenosylmethionine through glycine N-methyltransferase. That makes glycine a buffer on methyl group supply rather than a straightforward additive partner. Read it as mechanistic rather than clinical.

Homocysteine stands at a branch point. Methylcobalamin-dependent methionine synthase pulls it back toward methionine, while the transsulfuration branch sends it toward cystathionine and then cysteine. Intake of one arm shifts how much substrate reaches the other, so the relationship is directional rather than simply additive.

Food-bound cobalamin has to be freed from dietary protein in the stomach before haptocorrin can pick it up. Supplemental crystalline methylcobalamin is already free, so this step matters for food B12 and much less for the supplemental form. The distinction is worth stating plainly rather than presenting the pairing as a general absorption boost.

Cobalamin leaves the stomach bound to haptocorrin and can only move onto intrinsic factor after pancreatic proteases digest that carrier. This handover is a fixed step in the absorption chain, described in standard physiology. It is a mechanism statement, not a claim that added enzymes raise B12 status.

The cubilin and amnionless receptor pair in the ileum requires calcium ions to bind the intrinsic factor and cobalamin complex. Removing calcium from that step stops uptake in experimental systems. The dependency is textbook transport biochemistry and says nothing about supplemental calcium changing B12 status in a well-fed person.

Folate and cobalamin meet at the methionine synthase step, so generous folic acid can keep the haematological picture looking ordinary while the second cobalamin-dependent reaction, methylmalonyl-CoA mutase, remains starved. That is why methylmalonic acid is used alongside red cell measures. This is a masking interaction and it is well described in reference pharmacology.

When cobalamin becomes available after a long shortfall, marrow activity picks up quickly and the newly made cells take up potassium from plasma. Clinicians watch serum potassium during that phase for exactly this reason. The interaction belongs to a correction setting and not to routine maintenance intake.

Cobalamin readily exchanges its upper axial ligand, and cellular thiols such as cysteine and glutathione form thiolatocobalamin intermediates on the way to the active coenzyme forms. Supplemental thiol donors sit in that same chemical space. What this does to human B12 status has not been measured here, so the row stays mechanistic.

Inside the cell, cobalamin passes through a glutathionyl-bound form before being converted to methylcobalamin or adenosylcobalamin. Glutathione status therefore touches the processing route rather than the absorption route. No human combination outcome is claimed.

Cobalamin is made only by bacteria and archaea, and strains differ sharply in whether they produce it, consume it, or make corrinoids that occupy binding proteins without doing the work. Colonic synthesis sits mostly below the ileal absorption site, which limits how much reaches the body. This is an association at the level of microbial capability, not a demonstrated change in human B12 status.